First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

被引：22

作者：

O'Donnell, Peter H.

Balar, Arjun Vasant

Vuky, Jacqueline

Castellano, Daniel

Bellmunt, Joaquim

Powles, Thomas

Bajorin, Dean F.

Grivas, Petros

Hahn, Noah M.

Plimack, Elizabeth R.

Xu, Jin Zhi

Godwin, James Luke

Moreno, Blanca Homet

De Wit, Ronald

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[6] Queen Mary Univ London, Barts Canc Inst, London, England

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：3

共 50 条

[31] First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
Loriot, Yohann
Grivas, Petros
De Wit, Ronald
Balar, Arjun Vasant
Siefker-Radtke, Arlene O.
Zolnierek, Jakub
Csoszi, Tibor
Shin, Sang Joon
Park, Se Hoon
Atduev, Vagif
Gumus, Mahmut
Su, Yu-Li
Karaca, Saziye Burcak
Cutuli, Hernan
Sendur, Mehmet Nahit
Jia, Calvin
O'Hara, Karen
Franco, Sonia
Matsubara, Nobuaki
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[32] Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210
Balar, Arjun Vasant
Dreicer, Robert
Loriot, Yohann
Perez-Gracia, Jose Luis
Hoffman-Censits, Jean H.
Petrylak, Daniel Peter
Van Der Heijden, Michiel Simon
Ding, Beiying
Shen, Xiaodong
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] First-line (1L) enfortumab vedotin plus pembrolizumab demonstrates durable antitumour activity in cisplatin-ineligible patients with locally advanced/metastatic urothelial carcinoma (la/mUC)
Rosenberg, J. E.
Flaig, T. W.
Friedlander, T. W.
Milowsky, M. I.
Srinivas, S.
Petrylak, D. P.
Merchan, J. R.
Bilen, M. A.
Carret, A. -S.
Yuan, N.
Sasse, C.
Hoimes, C. J.
SWISS MEDICAL WEEKLY, 2020, : 26S - 27S
[34] Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905
Galsky, Matt D.
Necchi, Andrea
Shore, Neal D.
Witjes, Fred
Nam, Kijoeng
Sbar, Eric
Moreno, Blanca Homet
Plimack, Elizabeth R.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[35] Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).
Bajorin, Dean F.
De Wit, Ronald
Vaughn, David J.
Fradet, Yves
Lee, Jae-Lyun
Fong, Lawrence
Vogelzang, Nicholas J.
Climent, Miguel Angel
Petrylak, Daniel Peter
Choueiri, Toni K.
Necchi, Andrea
Gerritsen, Winald
Gurney, Howard
Quinn, David I.
Culine, Stephane
Sternberg, Cora N.
Mai, Yabing
Puhlmann, Markus
Perini, Rodolfo F.
Bellmunt, Joaquim
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible
Freshwater, Tomoko
Li, Haojie
Valiathan, Chandni
Li, Mengyao
Perini, Rodolfo
Bracco, Oswaldo L.
Frenkl, Tara
Keefe, Stephen
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (10): : 802 - 809
[37] Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
Borghaei, H.
Langer, C. J.
Gadgeel, S.
Papadimitrakopoulou, V. A.
Patnaik, A.
Powell, S. F.
Gentzler, R. D.
Martins, R. G.
Stevenson, J. P.
Jalal, S. I.
Panwalkar, A.
Yang, J. C-H.
Gubens, M.
Sequist, L.
Awad, M. M.
Fiore, J.
Saraf, S.
Raftopoulos, H.
Gandhi, L.
ANNALS OF ONCOLOGY, 2017, 28
[38] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial (vol 389, pg 67, 2017)
Balar, A., V
Galsky, M. D.
Rosenberg, J. E.
LANCET, 2017, 390 (10097): : 848 - 848
[39] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
Powles, Thomas
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem Airatovich
Hawkins, Robert E.
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris Yakovlevich
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio Jobim
Borchiellini, Delphine
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[40] FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)-Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement
Galsky, Matt D.
Powles, Thomas
Dreicer, Robert
Kitamura, Hiroshi
Asatiani, Ekatherine
Howe, Jason
Zhen, Huiling
Oliveira, Natalia
Necchi, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)

← 1 2 3 4 5 →